☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC October Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Sitagliptin (Januvia®) has been accepted for use in combination with a sulphonylurea or sulphonylurea and metformin in patients with type 2 diabetes who fail to achieve adequate glucose control while taking maximal tolerated doses.

Duloxetine (Cymbalta®) has been rejected for use in generalised anxiety disorder in the absence of a submission from the manufacturer.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC October Update' by emailShare 'SMC October Update' on FacebookShare 'SMC October Update' on TwitterShare 'SMC October Update' on LinkedInShare 'SMC October Update' on reddit


No Comments to “SMC October Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.